ExpreS2ion Biotech Holding AB (EXPRS2) AI Stock Analysis

ExpreS2ion Biotech Holding AB

(Nasdaq OMX AB:EXPRS2)

Select Model

Rating:41Neutral

Price Target:SEK 0.89▼(-4.50% Downside)

Action:reiterated

Date:08/27/26

The score is driven primarily by weak financial performance, with persistent losses, negative gross profitability, and continued cash burn outweighing the benefit of low leverage. Technicals add pressure as the stock trades below key moving averages with a negative MACD, signaling a downtrend. Valuation provides limited support because the negative P/E reflects ongoing losses and there is no dividend yield data.

Positive Factors

Low leverageVery low leverage reduces refinancing pressure and limits interest-related strain on the business. This gives ExpreS2ion greater financial flexibility than a heavily indebted biotechnology company while it works to improve profitability and fund development activities.

Negative Factors

Persistent unprofitable operationsNegative gross profit and substantial operating losses show that current revenue does not cover the cost base. Continued losses weaken the evidence for an economically scalable model and may require management to pursue significant improvements in pricing, volume, or operating efficiency.

ExpreS2ion Biotech Holding AB (EXPRS2) vs. iShares MSCI Sweden ETF (EWD)

Market Cap: SEK 36.86M
Dividend Yield: ―
Average Volume (3M): 125.59K
Price to Earnings (P/E): -0.1
Beta (1Y): 1.19
Revenue Growth: -2.29%
EPS Growth: 55.71%
Country: Sweden
Employees: 19
Sector: Healthcare
Sector Strength: 51
Industry: Biotechnology

ExpreS2ion Biotech Holding AB Business Overview & Revenue Model

Company Description

Based in Horsholm, Denmark, ExpreS2ion Biotech Holding AB, along with its subsidiary ExpreS2ion Biotechnologies, specializes in creating and manufacturing complex proteins for use in vaccines and diagnostic products. The company's development pipelin...

How the Company Makes Money

The company makes money primarily by monetizing its protein expression platform and associated capabilities through a mix of commercial offerings and business development arrangements. Key revenue streams include: (1) Contract research/services: prov...

ExpreS2ion Biotech Holding AB Financial Statement Overview

Summary

Overall fundamentals are weak: despite modest TTM revenue growth (~14.1%), profitability is the major issue (negative gross profit, large operating losses, deeply negative net margins) and cash flow remains materially negative with worsening free cash flow, implying ongoing funding needs. The main offset is low leverage (debt-to-equity ~0.05), which reduces near-term balance-sheet risk.

Income Statement

18Very Negative

Balance Sheet

63Positive

Cash Flow

16Very Negative

Financial statement breakdown
Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	3.84M	3.66M	3.01M	7.05M	5.09M	12.23M
Gross Profit	-40.52M	-42.84M	-2.67M	3.40M	5,000	4.72M
EBITDA	-61.07M	-51.35M	-64.34M	-102.45M	-124.49M	-46.38M
Net Income	-35.91M	-38.09M	-36.04M	-91.40M	-118.61M	-43.92M
Balance Sheet
Total Assets	57.79M	65.11M	104.53M	78.69M	137.36M	151.96M
Cash, Cash Equivalents and Short-Term Investments	34.38M	47.55M	81.54M	57.60M	110.97M	138.88M
Total Debt	1.45M	2.21M	1.80M	1.71M	1.85M	2.11M
Total Liabilities	16.02M	29.42M	40.11M	13.33M	34.04M	11.61M
Stockholders Equity	41.78M	35.69M	64.80M	65.36M	103.33M	140.35M
Cash Flow
Free Cash Flow	-35.27M	-40.90M	-34.80M	-102.90M	-100.00M	-46.36M
Operating Cash Flow	-47.77M	-40.90M	-33.93M	-100.89M	-99.61M	-45.65M
Investing Cash Flow	-307.00K	0	21.27M	-2.02M	105.33M	-100.92M
Financing Cash Flow	35.67M	10.78M	34.87M	47.84M	61.46M	74.55M

ExpreS2ion Biotech Holding AB Technical Analysis

Technical Analysis SentimentNegative

Last Price0.93

Price Trends

50DMA1.18Negative

100DMA1.31Negative

200DMA2.19Negative

Market Momentum

MACD-0.06Positive

RSI32.21Neutral

STOCH32.20Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:EXPRS2, the sentiment is Negative. The current price of 0.93 is below the 20-day moving average (MA) of 1.05, below the 50-day MA of 1.18, and below the 200-day MA of 2.19, indicating a bearish trend. The MACD of -0.06 indicates Positive momentum. The RSI at 32.21 is Neutral, neither overbought nor oversold. The STOCH value of 32.20 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SE:EXPRS2.

ExpreS2ion Biotech Holding AB Peers Comparison

Overall Rating

UnderperformOutperform

Sector (51)

Financial Indicators

SE:EXPRS2 against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
SE:CANTA	70Outperform	SEK 451.68M	2.35	63.09%	―	―	―
SE:XBRANE	53Neutral	SEK 291.57M	-5.90	-13.41%	―	-38.80%	-120.18%
Sector *	51Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
SE:BINV	43Neutral	SEK 357.32M	-0.73	-128.54%	―	-83.67%	-50.29%
SE:IMMU	43Neutral	SEK 348.89M	-3.07	-18.05%	―	―	15.97%
SE:IVACC	41Neutral	SEK 263.11M	-2.92	-34.25%	―	-0.71%	54.16%
SE:EXPRS2	41Neutral	SEK 36.86M	-0.14	-104.71%	―	-2.29%	55.71%

* Healthcare Sector Average

Performance Comparison

SE:EXPRS2 and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
SE:EXPRS2	ExpreS2ion Biotech Holding AB	0.93	-5.16	-84.67%
SE:BINV	BioInvent International AB	5.43	-28.47	-83.98%
SE:XBRANE	Xbrane Biopharma AB	14.15	3.35	31.02%
SE:IVACC	Intervacc AB	0.77	-0.20	-20.33%
SE:IMMU	Immunicum AB	5.50	-1.89	-25.58%
SE:CANTA	Cantargia AB	1.60	-1.97	-55.13%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Aug 27, 2026

ExpreS2ion Biotech Holding AB AI Stock Analysis